Donepezil

Donepezil

SCHEMBL1123745

COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl.O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 5/20 1.00
BCHE P06276 5/20 1.00
KDM4E B2RXH2 1/20 0.98
FAAH O00519 1/20 0.96
ABCC4 O15439 1/20 0.96
CACNA1F O60840 1/20 0.96
PDE5A O76074 1/20 0.96
ABCB11 O95342 1/20 0.96
APP P05067 1/20 0.96
CHRM2 P08172 1/20 0.96
ABCB1 P08183 1/20 0.96
CYP3A4 P08684 1/20 0.96
CHRM5 P08912 1/20 0.96
ADRA2A P08913 1/20 0.96
CHRM1 P11229 1/20 0.96
ADRA2C P18825 1/20 0.96
DRD4 P21917 1/20 0.96
SLC6A2 P23975 1/20 0.96
MAOB P27338 1/20 0.96
AGTR1 P30556 1/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Donepezil SCHEMBL4315806 1.00 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL4312618 1.00 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL29424585 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL356844 0.99 BCHE (0.98) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL3091472 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL1815 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL1559622 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL5060933 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL4979379 0.99 BCHE (0.98) BCHEACHEKDM4EFAAHABCC4
Donepezil SCHEMBL4256889 0.99 BCHE (1.00) BCHEACHEKDM4EFAAHABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021118004-A1 COMPLEX FORMULATION COMPRISING DONEPEZIL AND MEMANTINE 주식회사 종근당 2021-06-17 WO claimed
WO-2015109377-A1 PROCESS FOR PREPARING DONEPEZIL HYDROCHLORIDE FORMS I AND III; AND AN INTERMEDIATE COMPOUND THEREOF Cristália Produtos Químicos Farmacêuticos Ltda. (BR) 2015-07-30 WO claimed
US-20120283291-A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING DONEPEZIL HYDROCHLORIDE KRKA, TOVARNA ZDRAVIL D.D., NOVO MESTO (SI) 2012-11-08 US claimed
EP-2283811-A1 Solid pharmaceutical composition comprising donepezil hydrochloride Krka Tovarna Zdravil, D.D., Novo Mesto (SI) 2011-02-16 EP claimed
US-20100317694-A1 Solid pharmaceutical composition comprising donepezil hydrochloride KRKA, TOVARNA ZDRAVIL, D.D. , NOVO MESTO (SI) 2010-12-16 US claimed
US-20100055171-A1 Pharmaceutical Formulation Comprising Donepezil PLIVA HRVATSKA D.O.O. (HR) 2010-03-04 US claimed
US-7560560-B2 Crystalline forms of donepezil hydrochloride HETERO DRUGS LIMITED (US) 2009-07-14 US claimed
US-20090137811-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL PLIVA HRVATSKA D.O.O 2009-05-28 US claimed
US-20090130205-A9 Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride KRKA, TOVARNA ZDRAVIL D.D., NOVO MESTO (SI) 2009-05-21 US claimed
EP-2043618-A1 PHARMACEUTICAL FORMULATION COMPRISING DONEPEZIL PLIVA HRVATSKA d.o.o. (HR) 2009-04-08 EP claimed
US-20080063705-A1 Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride KRKA, TOVARNA ZDRAVIL D.D., NOVO MESTO (SI) 2008-03-13 US claimed
WO-2008012495-A1 PHARMACEUTICAL FORMULATION COMPRISING DONEPEZIL PLIVA HRVATSKA D.O.O. (HR) 2008-01-31 WO claimed
EP-1858848-A1 PROCESS FOR MAKING CRYSTALLINE DONEPEZIL HYDROCHLORIDE MONOHYDRATE Synthon B.V. (NL) 2007-11-28 EP claimed
EP-1811957-A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING DONEPEZIL HYDROCHLORIDE KRKA, tovarna zdravil, d.d., Novo mesto (SI) 2007-08-01 EP claimed
WO-2007015052-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL PLIVA ISTRAZIVANJE I RAZVOJ D.O.O. (HR) 2007-02-08 WO claimed
US-20060258705-A1 Process for making crystalline donepezil hydrochloride monohydrate SYNTHON BV (NL) 2006-11-16 US claimed
WO-2006097341-A1 PROCESS FOR MAKING CRYSTALLINE DONEPEZIL HYDROCHLORIDE MONOHYDRATE SYNTHON B.V. (NL) 2006-09-21 WO claimed
WO-2006045512-A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING DONEPEZIL HYDROCHLORIDE KRKA, TOVARNA ZDRAVIL (SI) 2006-05-04 WO claimed
US-20050215591-A1 Novel crystalline forms of donepezil hydrochloride HETERO DRUGS LIMITED (IN) 2005-09-29 US claimed
WO-2004092137-A1 NOVEL CRYSTALLINE FORMS OF DONEPEZIL HYDROCHLORIDE HETERO DRUGS LIMITED (IN) 2004-10-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137811-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL ACHE, BCHE, WIZ ACHE 1/4885BCHE 2/4885KDM4E 727/4885
US-20050215591-A1 Novel crystalline forms of donepezil hydrochloride ACHE, BCHE, MAPT ACHE 1/4885BCHE 2/4885KDM4E 437/4885
US-20060258705-A1 Process for making crystalline donepezil hydrochloride monohydrate CHRM2, C5, C9 ACHE 29/4885BCHE 4/4885KDM4E 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.